BiotechTube
Home/Noa Therapeutics/Kathy Kordy, MD
KK

Kathy Kordy, MD

CMO

Noa Therapeutics

Therapeutic Areas

ImmunologyGastroenterologyDermatology

Noa Therapeutics Pipeline

DrugIndicationPhase
Noa‑001Inflammatory Bowel DiseasePreclinical
Noa‑002Chronic Inflammatory Skin DisordersPreclinical

Leadership Team at Noa Therapeutics

CS
Carla Spina, PhD
CEO & Co‑Founder
SM
Serena Mandla, P.Eng, MASc
CSO & Co‑Founder
TD
Troy Dale, MBA
Acting CBO
View full Noa Therapeutics profile